Speaker Profile

Ph.D., Chief Scientific Officer, Affimed
Biography

Martin joined Affimed’s Management Team in 2015 as Chief Scientific Officer. He has a proven track record in preclinical and clinical biotherapeutic discovery, having established a broad research pipeline of programs in targeted cancer therapy and immuno-oncology. Martin has more than 15 years of professional experience. Prior to Affimed, Martin was co-founder and Chief Scientific Officer of CT Atlantic AG and co-founder of U3 Pharma AG. Martin graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the University of Würzburg, Germany. He earned his PhD working in Prof. Axel Ullrich’s group at the Max Planck Institute of Biochemistry in Martinsried-Munich, Germany.

Presentation Title and Company Description

Immunotherapy Showcase: Harnessing Innate and Adaptive Immunity to Treat Cancer
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.